Connect with us

Technology

Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

Published

2 hours ago

on

Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY® in the Retina Drug Delivery & New Targets Showcase at Eyecelerator 2026Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting, October 8–13, 2026, in New Orleans, Louisiana

DALLAS, Oct. 6, 2026 /PRNewswire/ — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that its optogenetics gene therapy (MOGENRY, MCO-010) will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) 2026 annual meeting taking place October 8–13, 2026, in New Orleans. Additionally, the company will participate in Eyecelerator@AAO 2026 with a company presentation and panel participation. Eyecelerator brings together ophthalmic innovators, industry leaders, clinicians, and investors to accelerate the development of new therapies and technologies in eye care. The AAO Annual Meeting is the world’s largest gathering of ophthalmologists and eye care professionals.

Presentation Details:

Eyecelerator 2026, Ernest N. Morial Convention Center

Panel: Emerging Innovations in Retinal Therapies

Panelist: Sam Barone, MD, Chief Medical Officer

Date & Time: Thursday, October 8, 2026, 10:45–11:30 AM CT

Location: La Nouvelle Ballroom C

Company Presentation: Retina Drug Delivery & New Targets Showcase

Presenter: Paul Hallen, Chief Operating Officer

Date & Time: Thursday, October 8, 2026, 1:00–1:05 PM CT

Location: Rooms 252–254

AAO 2026 Annual Meeting, Ernest N. Morial Convention Center

Presentation: Lasting Vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial of MCO-010 Optogenetic Therapy

Session: PA044

Presenter: Kenneth C. Fan, MD

Date & Time: Sunday, October 11, 2026, 11:42–11:49 AM CT

Location: Rooms 255–257

Scientific Poster: Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT

Session: PO624

Presenter: David S. Boyer, MD

Availability: On demand

During the panel, Dr. Barone will join fellow industry leaders to discuss emerging approaches in retinal therapeutics, including the potential of mutation-agnostic optogenetic gene therapy for patients with advanced retinal degeneration. In the Showcase presentation, Mr. Hallen will provide an update on Nanoscope’s progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company’s Biologics License Application (BLA), and Japan New Drug Application (JNDA), currently under FDA and PMDA review respectively. At AAO 2026, Dr. Fan will present four-year data from the REMAIN study of patients treated in the RESTORE Phase 2b/3 trial, highlighting the durability of vision improvement with MCO-010 in retinitis pigmentosa. Dr. David S. Boyer will also present a scientific poster, available on demand, on vision improvement with sonpiretigene isteparvovec in dry AMD from the first direct-to-Phase 2 randomized controlled trial. Members of the Nanoscope leadership team will be available to meet with retina specialists, investors, and potential partners throughout Eyecelerator and AAO 2026.

Nanoscope team members will be available at Booth 2564 for the duration of the AAO conference.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)

Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan. The 2026 Nobel Prize in Physiology or Medicine was recently awarded to the three scientists who pioneered optogenetics, the scientific foundation that Nanoscope’s development programs, including MOGENRY, are built upon.

About Nanoscope Therapeutics

Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY, and the PMDA has accepted for priority review the Company’s NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).

Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.

Contact:

Nanoscope Therapeutics, Inc

(817) 857-1186

PR@nanostherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting-302899515.html

SOURCE Nanoscope Therapeutics

Related Topics:
Continue Reading

Technology

New Cornerstone Advisors Research Reveals Community Banks Are Ceding a $106 Billion Consumer Lending Opportunity

Published

39 seconds ago

on

October 6, 2026

By

Study finds consumer lending can protect commercial relationships, deposits and future growth

SCOTTSDALE, Ariz., Oct. 6, 2026 /PRNewswire/ — Community banks that treat consumer lending as a low-margin, low-priority product risk surrendering valuable customer relationships and billions in loan demand to competitors, according to new Cornerstone Advisors research commissioned by Teslar Software.

The report, The Most Valuable Loan Community Banks Don’t Make: The Hidden Value of Consumer Lending, says consumer lending should be viewed not as a standalone profit center but as a way to retain business-owner relationships, protect deposits and defend against fintechs, credit unions and large banks.

Across approximately 5.5 million U.S. employer small businesses, owners are expected to generate roughly $106 billion in consumer loan demand over the next two years — much of which community banks currently allow to flow elsewhere. The study, based on a survey of 1,249 small-business owners and executives and interviews with community bank executives, found that nearly 60% of business owners bank with one of the five largest U.S. banks, where consumer lending represents 12% to 24% of total loan portfolios.

Additionally:

Median consumer loans are just 1.2% of total loans at U.S. banks with $500 million to $20 billion in assets and 0.83% at banks with $10 billion to $20 billion.Only 46% of business owners who obtained a personal loan in the past three years used their primary business bank; 54% borrowed elsewhere.Business owners cited rates or terms (41%), slow approval (35%) and lack of awareness or availability (14%) as reasons for borrowing elsewhere.

“Many banks ask whether consumer loans generate enough profit on their own to justify the investment,” said Elizabeth Gujral, director at Cornerstone Advisors. “The real question is what banks stand to lose when business owners turn elsewhere. Every loan that leaves creates an opening for a competitor to deepen the relationship, attract deposits and win future business. Consumer lending is increasingly a relationship-retention strategy.”

Other key survey findings:

72% of business owners expect to need a consumer loan within three years, up from 66% who obtained one in the previous three years.80% would consider a consumer loan from their primary business bank if it offered the product.Banks with the highest consumer lending mix outperformed those with the lowest, posting median ROA of 1.44% versus 1.15%, ROE of 13.4% versus 10.5%, and deposit growth of 9.9% versus 8.0%.

“Consumer lending is about more than the loan itself,” said Joe Ehrhardt, CEO and founder of Teslar Software. “It’s an opportunity to deepen existing relationships today and build the commercial relationships of tomorrow. By modernizing origination and automating routine processes, community institutions can make consumer lending efficient and profitable while supporting long-term growth.”

The report concludes that although consumer lending may not drive profits on a loan-by-loan basis, it plays a critical role in strengthening customer relationships and defending against growing competition.

The full report, The Most Valuable Loan Community Banks Don’t Make: The Hidden Value of Consumer Lending, is available for download here.

About Cornerstone Advisors

For more than 20 years, Cornerstone Advisors has provided advisory services and research to banks, credit unions and fintech companies. The firm helps financial institutions improve performance, modernize technology, increase efficiency and execute growth strategies.

About Teslar Software

Teslar Software helps community financial institutions modernize operations and accelerate growth while preserving relationship banking. Its unified platform supports loan origination, portfolio management, AI-powered workflow automation and exception tracking.

Media Contact
Cate Pitts, Editorial Director
Cornerstone Advisors
480-425-5203
424179@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-cornerstone-advisors-research-reveals-community-banks-are-ceding-a-106-billion-consumer-lending-opportunity-302899390.html

SOURCE Cornerstone Advisors

Continue Reading

Technology

New Cornerstone Advisors Research Reveals Community Banks Are Ceding a $106 Billion Consumer Lending Opportunity

Published

39 seconds ago

on

October 6, 2026

By

Study finds consumer lending can protect commercial relationships, deposits and future growth

SCOTTSDALE, Ariz., Oct. 6, 2026 /PRNewswire/ — Community banks that treat consumer lending as a low-margin, low-priority product risk surrendering valuable customer relationships and billions in loan demand to competitors, according to new Cornerstone Advisors research commissioned by Teslar Software.

The report, The Most Valuable Loan Community Banks Don’t Make: The Hidden Value of Consumer Lending, says consumer lending should be viewed not as a standalone profit center but as a way to retain business-owner relationships, protect deposits and defend against fintechs, credit unions and large banks.

Across approximately 5.5 million U.S. employer small businesses, owners are expected to generate roughly $106 billion in consumer loan demand over the next two years — much of which community banks currently allow to flow elsewhere. The study, based on a survey of 1,249 small-business owners and executives and interviews with community bank executives, found that nearly 60% of business owners bank with one of the five largest U.S. banks, where consumer lending represents 12% to 24% of total loan portfolios.

Additionally:

Median consumer loans are just 1.2% of total loans at U.S. banks with $500 million to $20 billion in assets and 0.83% at banks with $10 billion to $20 billion.Only 46% of business owners who obtained a personal loan in the past three years used their primary business bank; 54% borrowed elsewhere.Business owners cited rates or terms (41%), slow approval (35%) and lack of awareness or availability (14%) as reasons for borrowing elsewhere.

“Many banks ask whether consumer loans generate enough profit on their own to justify the investment,” said Elizabeth Gujral, director at Cornerstone Advisors. “The real question is what banks stand to lose when business owners turn elsewhere. Every loan that leaves creates an opening for a competitor to deepen the relationship, attract deposits and win future business. Consumer lending is increasingly a relationship-retention strategy.”

Other key survey findings:

72% of business owners expect to need a consumer loan within three years, up from 66% who obtained one in the previous three years.80% would consider a consumer loan from their primary business bank if it offered the product.Banks with the highest consumer lending mix outperformed those with the lowest, posting median ROA of 1.44% versus 1.15%, ROE of 13.4% versus 10.5%, and deposit growth of 9.9% versus 8.0%.

“Consumer lending is about more than the loan itself,” said Joe Ehrhardt, CEO and founder of Teslar Software. “It’s an opportunity to deepen existing relationships today and build the commercial relationships of tomorrow. By modernizing origination and automating routine processes, community institutions can make consumer lending efficient and profitable while supporting long-term growth.”

The report concludes that although consumer lending may not drive profits on a loan-by-loan basis, it plays a critical role in strengthening customer relationships and defending against growing competition.

The full report, The Most Valuable Loan Community Banks Don’t Make: The Hidden Value of Consumer Lending, is available for download here.

About Cornerstone Advisors

For more than 20 years, Cornerstone Advisors has provided advisory services and research to banks, credit unions and fintech companies. The firm helps financial institutions improve performance, modernize technology, increase efficiency and execute growth strategies.

About Teslar Software

Teslar Software helps community financial institutions modernize operations and accelerate growth while preserving relationship banking. Its unified platform supports loan origination, portfolio management, AI-powered workflow automation and exception tracking.

Media Contact
Cate Pitts, Editorial Director
Cornerstone Advisors
480-425-5203
424179@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-cornerstone-advisors-research-reveals-community-banks-are-ceding-a-106-billion-consumer-lending-opportunity-302899390.html

SOURCE Cornerstone Advisors

Continue Reading

Technology

Itibari-Waynne & Partners (IWP) and VYRE Activate Partnership with Exclusive Content for VBNGtv

Published

41 seconds ago

on

October 6, 2026

By

First Projects Announced: ‘The Plug’ and Season Two of ‘self!’ as IWP prepares to open in early 2027

LOS ANGELES, Oct. 6, 2026 /PRNewswire/ — Itibari-Waynne & Partners (IWP), the agentic financing platform for creator-led projects, and VYRE Network are kicking off their partnership with the launch of content created exclusively for VYRE Business News Global (VBNGtv), VYRE’s free streaming business channel.

With IWP officially opening for business in the first quarter of 2027, they are inviting creators, investors, lenders, vendors and apprentices to get a headstart where projects meet capital right now. Join their “Reserve Your Spot Today!” campaign today and Plug In to gain first access to funding.

“When we announced this partnership, the goal was to bring capital and content together on one network. Today that becomes real,” said David Hill, CEO of VYRE Network. “VBNGtv viewers get exclusive programming about business and capital, and creators get a direct line to IWP’s financing platform.”

‘The Plug’: First Proven Project

Debuting this fall, ‘The Plug’ is a video podcast series hosted by Grammy Award-winning producer Bruce Waynne, Founder and CEO of IWP, and Itibari Zulu, President of IWP and Chief Investment Officer of VYRE. It features long-form conversations with entrepreneurs, financiers, investors and entertainers about access to capital, ownership and building a company.

Named after PLUG, IWP’s dedicated funding agent, the series puts IWP’s model in front of the audience it serves: creators seeking funding, investors and lenders seeking vetted deals, and vendors and apprentices seeking funded work.

‘The Plug’ is also the first project financed under IWP’s model and serves as its proof of concept. The model layers risk protection with identifiable repayment sources; depending on the transaction, up to 80% of financing may be supported by insurance-backed credit enhancements, government incentives, tax credits, minimum guarantees, presales and distribution commitments.

‘self!’: IWP Helps Fund Second Season

IWP is contributing funding for Season Two of the successful VBNGtv original series, ‘self!’ which stands for Self-Empowerment Lessons Flourished. The recorded presentation-style talks provide an open-door look at how influential business leaders have elevated their companies to the next level.

The highest viewed episode from the first season featured a candid account from Itibari Zulu, who reveals how he found motivation and transformed it into a successful career in the financial services industry for over two decades. Watch this ‘self!’ episode now: ‘Itibari Zulu – Understanding the 4 Phases in Business’ 

“‘self!’ gave me the chance to share my story,” adds Zulu. “Season Two is about helping more people tell theirs, and that’s what IWP was built to do: put capital behind the people doing the work.”

Both ‘The Plug’ and ‘self!’ can be streamed for free at VBNGtv.com, the VYRE app, and on Roku, Amazon Fire TV, Apple TV, Samsung and LG Smart TVs, iOS and Android.

About IWP
IWP is an agentic financing platform that provides the infrastructure layer for entrepreneurs, powered by PLUG, its dedicated funding agent. www.iwp.fund

About VBNGtv
VBNGtv is a capital markets media engine and global streaming business channel showcasing small-cap and micro-cap companies, business leaders and brand partners.

About VYRE Network
VYRE is a vertically integrated media and entertainment technology company that helps creators, studios and brands distribute, finance, market and monetize premium content worldwide.

Media Contact:
Tammy Lynn, Spotlight PR Company
310-867-1952 / 424183@email4pr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/itibari-waynne–partners-iwp-and-vyre-activate-partnership-with-exclusive-content-for-vbngtv-302899709.html

SOURCE Itibari-Waynne & Partners (IWP)

Continue Reading

Trending